Latest Australian Market News

Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.

Variscan Mines Limited has voluntarily suspended trading on the ASX pending a Supreme Court decision related to a regulatory compliance issue with a past share issue. The suspension highlights ongoing legal scrutiny and investor uncertainty.

Rhythm Biosciences has achieved a significant regulatory milestone with NATA accreditation for its ColoSTAT® blood-based colorectal cancer test, enabling its commercial rollout in Australia and strengthening reimbursement prospects.

RLF AgTech has built a promising $3 million sales pipeline in Australia from scratch while securing $7.2 million in pre-paid orders in China, signalling robust growth ahead of the 2026 season.

S&P Dow Jones Indices has announced its March 2026 quarterly rebalance, reshuffling key constituents across major S&P/ASX indices effective March 23. The update signals shifts in market representation with notable additions and removals.

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

FBR Limited has locked in a binding $400,000–$450,000 Wall as a Service® contract with AMOVEO, marking a key step in deploying its Hadrian® robotic construction technology at scale. The company also inked a strategic MOU to pilot a hybrid robotic-modular housing solution targeting Australia’s affordable housing shortage.

Stockland has formalised a 50/50 partnership with EdgeConneX to develop and operate a portfolio of hyperscale data centres across Australia, blending local property expertise with global data centre know-how.

The ACCC has advanced its Phase 2 review of Ampol’s proposed acquisition of EG Australia, identifying fewer sites of competition concern but maintaining scrutiny over key metropolitan markets.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

Channel Infrastructure reported steady FY25 financials with record throughput and key project progress, while raising dividends and expanding into Australia via a strategic pipeline stake.

PointsBet Holdings Limited reports a 4% revenue increase in H1 FY26 following MIXI’s acquisition of a controlling stake, with contrasting performances in Australia and Canada shaping the group’s outlook.